Molecular and Genetic Medicine

Hospital Santa Paula, São Paulo, SP, Brazil

Publications

• Review Article   
  Seroconversion for SARS-CoV-2 in Rheumatic Patients on Synthetic and Biologics Disease Modifying Anti-Rheumatic Drugs in São Paulo, Brazil
  Author(s): Santana FM, Lopes JB, Perez MO, Campana G, Levi JE, Lopes FPPL, Gebara OE, Cobra JF and Figueiredo CP*
  
  Introduction: There is a lack of information on how immunomodulatory drugs for autoimmune rheumatic diseases (ARDs) impair humoral immune response following SARS-CoV-2 exposure. Methods: A prospective study was performed with ARD patients on synthetic or biologic DMARDs (sDMARDs or bDMARDs) classified into three groups (antimalarial monotherapy, antimalarial plus bDMARD, antimalarial plus sDMARD) and a fourth group (control). All patients underwent a clinical baseline interview, anti-SARS-CoV-2 IgG/IgM tests at baseline and three months later, monitored for incident respiratory symptoms at follow-up, with rRT-PCR in suspected cases. Results: One hundred patients were included. Fewer than half who turned IgG positive (42.8%) remained asymptomatic. All three positive rRT-PCR patients showed seroconver.. Read More»
  DOI: 10.37421/1747-0862.2021.s1.482

  Abstract HTML PDF